Immunome Inc
IMNM10.300USD
+0.350+3.52%
Fechamento 08/22, 16:00（ET）Cotações atrasadas em 15 min
896.23MValor de mercado
PerdaP/L TTM
Mais detalhes de Immunome Inc Empresa
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.
Informações da empresa
Código da empresaIMNM
Nome da EmpresaImmunome Inc
Data de listagemOct 02, 2020
CEODr. Clay B. Siegall, Ph.D.
Número de funcionários118
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 02
Endereço18702 N. Creek Parkway
CidadeBOTHELL
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal98011
Telefone16103213700
Sitehttps://immunome.com/
Código da empresaIMNM
Data de listagemOct 02, 2020
CEODr. Clay B. Siegall, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Dr. Phil Tsai
Dr. Phil Tsai
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Sandra M Swain, M.D.
Dr. Sandra M Swain, M.D.
Independent Director
Independent Director
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
2.93M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
9.51%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
5.94%
Redmile Group, LLC
5.60%
Enavate Sciences GP, LLC
5.48%
Outro
66.39%
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
9.51%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
5.94%
Redmile Group, LLC
5.60%
Enavate Sciences GP, LLC
5.48%
Outro
66.39%
Tipos de investidores
Investidores
Proporção
Investment Advisor
43.04%
Investment Advisor/Hedge Fund
24.45%
Hedge Fund
12.05%
Corporation
8.25%
Research Firm
5.75%
Individual Investor
1.69%
Venture Capital
0.89%
Bank and Trust
0.31%
Pension Fund
0.20%
Outro
3.36%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
326
85.20M
99.48%
+13.79M
2025Q1
320
89.38M
113.71%
+17.13M
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
2023Q2
81
5.83M
36.98%
+582.43K
2023Q1
95
4.18M
34.54%
-644.30K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
T. Rowe Price Investment Management, Inc.
7.55M
8.68%
+2.05M
+37.36%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.89M
4.47%
-26.90K
-0.69%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.11M
5.87%
+1.37M
+36.49%
Mar 31, 2025
Redmile Group, LLC
5.36M
6.16%
+533.16K
+11.04%
Mar 31, 2025
Enavate Sciences GP, LLC
4.77M
5.48%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
4.36M
5.01%
+3.67M
+533.09%
Mar 31, 2025
The Vanguard Group, Inc.
4.29M
4.93%
+1.29M
+43.20%
Mar 31, 2025
EcoR1 Capital, LLC
4.08M
4.69%
+200.00K
+5.16%
Mar 31, 2025
Opaleye Management Inc.
3.55M
4.08%
+1.51M
+74.02%
Mar 31, 2025
PRIMECAP Management Company
3.41M
3.92%
+3.13M
+1115.71%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 6 de ago
Atualizado em: qua, 6 de ago
Nome
Proporção
Tema Oncology ETF
1.65%
iShares Genomics Immunology and Healthcare ETF
1.64%
WisdomTree BioRevolution Fund
1.01%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
ALPS Medical Breakthroughs ETF
0.55%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
iShares Russell 2000 Growth ETF
0.05%
iShares US Tech Breakthrough Multisector ETF
0.04%
Ver Mais
Tema Oncology ETF
Proporção1.65%
iShares Genomics Immunology and Healthcare ETF
Proporção1.64%
WisdomTree BioRevolution Fund
Proporção1.01%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.86%
ALPS Medical Breakthroughs ETF
Proporção0.55%
SPDR S&P Biotech ETF
Proporção0.2%
iShares Micro-Cap ETF
Proporção0.15%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.13%
iShares Russell 2000 Growth ETF
Proporção0.05%
iShares US Tech Breakthrough Multisector ETF
Proporção0.04%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
